Bryan, Garnier & Co advises Cellectis on its acquisition of Cellartis and EUR 50 million capital increase
Share the transaction
Paris – November, 5th, 2011 – Bryan, Garnier & Co, the independent pan-European investment bank focused on European growth companies, today announced it has advised Cellectis on its acquisition of Cellartis and EUR 50 million capital increase.
Cellectis confirms the completion of the acquisition of Cellartis, a Swedish company leading European R & D tools in vitro-derived stem cells. This results in an emission of 1,933,333 shares Cellectis to former shareholders of Cellartis, as well as the completion of the issuance of 6,250,000 bonds redeemable in shares for a total amount of 50 million Euros, subscribed equally by the Strategic Investment Fund (FSI) and Mr. Pierre Bastid.
Bryan Garnier & Co acted as co-advisor to Cellectis on this transaction.
For more information, please contact:
Christian Finan – Director Equity Capital Markets / +33 1 56 68 75 30 / cfinan@bryangarnier.com
Catherine Trividic – Director Healthcare / +33 1 56 68 75 05 | ctrividic@bryangarnier.com
Hervé Ronin – Director Healthcare / +33 1 70 36 57 22 / hronin@bryangarnier.com
Raquel Pires – Analyst – Corporate Finance / +33 1 56 68 75 38 / rpires@bryangarnier.com
About Cellartis
Formed as a spin-off from the University of Gothenburg, Cellartis is a Swedish company with 10 years’ active experience in the development, industrialization and marketing of stem cell-derived cardiomyocytes and hepatocytes. These differentiated cells are currently mainly used for research and pharmaceutical clinical trials, and they offer unrivalled performance in toxicity testing.
Cellartis’ unique position is based on its ownership and exploitation of the largest stem cell bank in the world (30 proprietary lines) and on the expertise in differentiation technologies that the company has developed since it was set up. The industrial rollout of these technologies has led to the creation of two certified sites in Sweden and Scotland.
Alongside leading partners, Cellartis is involved in regenerative medicine programs which use the immense potential of stem cells for the restoration of damaged tissues and organs.
Cellartis has 62 employees, all with a high level of scientific and industrial expertise. The company’s turnover in 2010 was SEK 34.3M. At June 30th, 2011, its shareholder equity was SEK 2.6M and its net cash SEK 7.5M (unaudited figures).
About Cellectis
Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.